The company also has active partnership programs with both patients and providers.
“We have a dedicated team of individuals who come to work every day and focus only on eye care, thinking about innovation and collaborating with patients and physicians across the country,” Valorie said. “We want to make sure that we get every product right as we continue to generate opportunities for the future.”
The vision consumer and vision care portfolio includes new contact lens platforms utilizing novel materials and a heavy manufacturing investment in Rochester, NY. The consumer health side includes solutions to support contact lens users, as well as products that span from dry eye and vitamins to allergy to multi-purpose solutions.
The premium vision cataract portfolio includes the Victus Femtosecond Laser System, Stellaris Vision Enhancement System, enVista IOLs, and toric IOLs under the Crystalens and Trulign brands.
Retina surgery includes the Stellaris system as well as retina accessories, including single-use instruments, laser probes, illuminators, chandeliers, and more. The pharmaceutical ophthalmic portfolio includes over a dozen familiar names backed by an access program that is supported by Walgreens and participating independent pharmacies to improve patient access.
“Our access program allows us the ability to offer patients very low cost for all of the pharmaceutical products in our portfolio,” Valorie said. “The most important consideration is that patients have access to physicians who can prescribe the product they most want for each specific patient and ensure that patients are not inhibited by cost.”